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The use of gene transduction by viral vectors in human gene therapy is currently attracting a great deal of attention. In cancer therapy, gene therapy is expected to play a key role in next-generation treatments, as well as in complementing conventional treatment modalities, such as surgery, chemotherapy, and radiotherapy. 1, 2) Adenovirus vectors (Adv) have been very useful in clinical gene therapy because of their ability to propagate to a high titer and efficiently transduce cells and tissues regardless of the mitotic status of the cells. 3, 4) Intratumoral injection of Adv has demonstrated therapeutic efficacy against primary tumors in several clinical trials. 5, 6) However, the clinical application of Adv has been limited by several problems. The systemic administration of Adv can lead to the acute accumulation of Adv and transgene expression in the liver, which may cause marked hepatotoxicity and activate the acquired immune response. 4, 7) Since systemic administration is required to treat distant metastases, it is currently difficult to use Adv to treat metastatic tumors, which are the major cause of mortality from cancer. Furthermore, because neutralizing antibodies (Abs) to Adv are highly prevalent in the human population, administration of high doses of Adv, which are needed to obtain sufficient therapeutic effects, causes negative side-effects. 8, 9) In addition, neutralizing anti-Adv Abs are produced after administration of Adv in animal models. 10, 11) These preexisting or Adv-induced Abs can adversely affect the therapeutic effect of the Adv by attenuating the level of transgene expression.
Covalent conjugation of polyethleneglycol (PEG) to the Adv surface, by a process called "PEGylation," is the one of the promising strategies to overcome these limitations. 4, 12, 13) Because of the steric hindrance of the PEG molecule, PEGylation can prolong the plasma half-life of molecules, prevent hepatic uptake, and alter the tissue distribution of the conjugates compared with the native form. 14, 15) The extended circulating lifetime in the blood induces the "enhanced permeability and retention" (EPR) effect, which is due to the leaky nature of tumor blood vessels. This effect results in increased delivery of the conjugates to tumor tissue. 16) We have examined the in vitro and in vivo characteristics of PEGylated Adv (PEG-Ad) manufactured using PEG of various molecular weights, and with various PEG modification rates. 17, 18) With optimized modification conditions, PEG-Ad showed higher accumulation rates and transgene expression in tumors than unmodified Adv after systemic administration, due to the EPR effect. 17, 18) Furthermore, we showed that PEG-Ad encoding a therapeutic gene produced both stronger tumor-suppressive activity and fewer hepatotoxic side effects than unmodified Adv, suggesting that systemic administration of PEG-Ad has great potential for systemic cancer gene therapy. 17, 18) In addition, we and others have reported that PEG-Ad can evade pre-existing neutralizing anti-Adv Abs, thereby making repeated vector delivery to liver and lung feasible. 10, [19] [20] [21] ing the efficacy of PEG-Ad in reducing the production of neutralizing anti-Adv Abs. Although some reports show that mucosal administration of PEG-Ad reduces the production of neutralizing anti-Adv Abs, 10, 22) no study has been carried out to examine the production of neutralizing anti-Adv Abs after systemic administration of PEG-Ad. In addition, PEG modification rates significantly affect many properties of PEGAd, 17, 18) but the PEG modification rate that is optimal for the reduction of neutralizing anti-Adv Abs is not known.
In this study, we focused on the effect of PEGylation of Adv on the production of neutralizing anti-Adv Abs. We examined the level of anti-Adv immunoglobulin (Ig)G and IgM in serum after systemic administration of Adv modified with 5-kDa PEG, which is most frequently used for PEGylation of Adv. In addition, we assessed the antitumor effect of systemically injected PEG-Ad in lung metastasis-model mice.
MATERIALS AND METHODS

Animals and Cell Lines
Female 5-week-old C57BL/6 mice and male 5-week-old Wistar rats were purchased from SLC Inc. (Hamamatsu, Japan) and kept under pathogen-free conditions in our animal facility before use. All of the animal experimental procedures in this study were performed in accordance with the Osaka University guidelines for the welfare of animals. The HEK293 cell-line (derived from normal human embryonic kidney fibroblasts) was obtained from the Japanese Collection of Research Bioresources (Tokyo, Japan). HEK293 cells were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St. Louis, MO, U.S.A.) containing 10% fetal bovine serum (FBS) and antibiotics. B16BL6 melanoma cells, which cause lung metastases when introduced into mice, were cultured in minimal essential medium (Sigma-Aldrich) containing 7.5% FBS and antibiotics.
Construction of the Adv An improved in vitro ligation method 23, 24) was used to construct an E1-E3-deleted adenovirus type 5 vector expressing firefly luciferase or tumor necrosis factor alpha (TNFa) under the control of the cytomegalovirus (CMV) promoter (Adv-CMV/Luc and Adv-CMV/TNFa, respectively). Each Adv was amplified in HEK293 cells using established methods.
18) The concentration of virus particles (vp) was measured by spectrophotometry, 25) and the biological titer was determined by using the Adeno-X Rapid Titer Kit protocol (Clontech Laboratories, Mountain View, CA, U.S.A.). The ratio of particle concentration to biological titer of each Adv was between 10 and 40.
PEGylation of Adv Adv were covalently attached to activated methoxypolyethylene glycol-succinimidyl succinate (SUNBRIGHT ME-050 CS; molecular weight, 5000; NOF, Tokyo, Japan). Briefly, Adv were incubated with activated PEG at 50-, 200-or 800-fold molar excess at 37°C for 45 min with gentle stirring to allow modification of the viral lysine residues. The modification rate of each PEG-Ad was determined by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) analysis, as described previously. 17, 18) Analysis of Adv-Specific Abs Male 7-week-old Wistar rats were intravenously administered with 10 11 vp of Adv or PEG-Ad expressing luciferase, or phosphate buffered saline (PBS) as a control. After 5 d, blood samples were collected and the levels of anti-Adv IgG and anti-Adv IgM in serum were determined by enzyme-linked immunosorbent assay (ELISA).
ELISA ELISA plates (Maxisorp, type 96F; Nalge Nunc International, Tokyo, Japan) were coated with 5 mg/ml goat anti-Adv polyclonal Ab (Chemicon, Billerica, MA, U.S.A.). After non-specific binding was blocked by incubation with blocking solution, Adv (5ϫ10 9 vp/ml) was added and the plates were incubated at 37°C for 2 h. The coated plates were washed with PBS-Tween 20 and incubated with 50-fold diluted serum samples at 37°C for 2 h. The coated plates were then rewashed with PBS-Tween 20 and incubated with a horseradish peroxidase (HRP)-conjugated goat anti-rat IgG solution (SouthernBiotech, Birmingham, AL, U.S.A.) or an HRP-conjugated goat anti-rat IgM solution (SouthernBiotech) at room temperature for 2 h. After incubation, the color reaction was developed with tetramethylbenzidine (MOSS, Inc. Pasadena, MD, U.S.A.), stopped with 2 N H 2 SO 4 and the Ab level was measured as OD 450 minus OD 655 by using a microplate reader.
Therapeutic Study B16BL6 cells (3ϫ10 5 cells/mouse) were injected into the tail vein of female 6-week-old C57BL/6 mice. After 7 d, Adv expressing TNFa (3ϫ10 10 vp) were intravenously injected into the mice. Serum levels of glutamic oxaloacetic transaminase (GOT) and glutamicpyruvic transaminase (GPT), which are commonly used in liver function tests as indicators of hepatotoxicity, were measured on day 7 after Adv injection by using the Transaminase CII-test (Wako Pure Chemical, Osaka, Japan), according to the manufacturer's instructions. On the same day, the lungs fixed in Bouin's solution for 24 h. The number of metastatic colonies on the surface was then counted.
Statistical Analysis All results are presented as meanϮ standard error of the mean (S.E.M.). The means of different groups were compared by analysis of variance (ANOVA), and the p values were adjusted for multiple testing by the Bonferroni correction. p values Ͻ0.05 were considered statistically significant.
RESULTS AND DISCUSSION
Optimal Modification Rate of PEG for Reducing the Production of Anti-Adv Abs
We evaluated the effect of the modification rate of PEG-Ad on the production of antiAdv Abs in vivo. Using 5-kDa PEG, which is the most frequently used for PEGylation of Adv, we constructed a set of PEG-Ad with three different modification rates (30%, 45%, 90%), which we termed PEG-Ad (30%), PEG-Ad (45%) and PEG-Ad (90%), respectively. Wistar rats were intravenously administered with PBS or 10 11 vp of unmodified Adv, PEGAd (30%), PEG-Ad (45%) or PEG-Ad (90%). We used rats for the evaluation of the production of anti-Adv Abs, because rats could produce anti-Adv Abs efficiently compared to mice. After 5 d, the level of anti-Adv IgG (Fig. 1A) and antiAdv IgM (Fig. 1B ) in serum were determined by ELISA. The level of anti-Adv IgG in rats treated with unmodified Adv, PEG-Ad (30%), or PEG-Ad (45%) was significantly higher than that in PBS-treated control rats. In contrast, the level of anti-Adv IgG in rats treated with PEG-Ad (90%) was comparable to the levels in PBS-treated control rats, and significantly lower than the levels in rats treated with unmodi-fied Adv. Similarly, the level of anti-Adv IgM in rats treated with PEG-Ad (90%) was comparable to that in the PBStreated control rats, and lower than that in rats treated with unmodified Adv; however, the trends were not statistically significant in this case. These results suggest that PEG-Ad (90%) is the optimal PEGylated condition for reducing the production of anti-Adv Abs. Splenic dendritic cells are responsible for Adv-mediated innate immunity including production of inflammatory cytokines and chemokines, leading to anti-Adv Abs production. 7) We and others have previously demonstrated that PEG-Ad can prolong the circulation time in blood and decrease the innate immune responses that occur after Adv injection, as the PEG modification ratio increased, because the steric hindrance of the high-density PEG chains prevents contact between PEG-Ad and immune cells. 10, 17, 18, 26) Therefore we consider that PEG-Ad (90%) could overcome the hurdle of immune response against Adv by the alteration of cellular uptake.
Therapeutic Effect of PEG-Ad on Metastasis Unresectable cancers in brain, lung, pancreas and other organs remain the major cause of morbidity and mortality in cancer patients, and are one of the most formidable problems in clinics. In lung cancer, for example, despite the use of chemotherapy and radiation therapy in combined-modality protocols, local control rates are Ͻ20%. Because we observed that use of PEG-Ad (90%) minimized the production of anti-Adv Abs, we focused on PEG-Ad (90%) for the study of the therapeutic effects of PEG-Ad. In a previous study, we showed that treatment with PEG-Ad (90%) encoding TNFa as a therapeutic gene produces stronger tumor-suppressive activity against primary tumors and fewer hepatotoxic side effects than treatment with unmodified Adv 17) ; however, it was not clear whether PEG-Ad (90%) treatment has a therapeutic effect against tumor metastasis. Here, we assessed intravenous injections of PEG-Ad (90%) expressing TNFa (Fig. 2) for their therapeutic effect against metastases. Commonly used metastasis-model mice were produced by injecting C57BL/6 mice with B16BL6 cells. We intravenously administered the metastasis-model mice with 3ϫ10 10 vp of unmodified Adv or PEG-Ad and assessed the therapeutic effect. Multiple metastatic colonies were observed on the surface of the lungs of mice treated with unmodified Adv, and the total number was not significantly different to the number in PBS treated control mice. In contrast, systemic treatment with PEG-Ad (90%) significantly reduced the number of metastatic colonies, when compared to treatment with PBS or un- modified Adv.
We then evaluated the treatment side-effects by measuring the levels of two hepatotoxicity indicators, GOT and GPT, in the serum (Fig. 3) . Injection of unmodified Adv induced significantly elevated levels of GOT and GPT, presumably due to increased expression of these enzymes in liver. In contrast, intravenous injection of PEG-Ad (90%) did not significantly increase the levels of GOT or GPT. These data suggest that PEG-Ad (90%) is a prototype vector with suitable efficacy and safety for use in systemic cancer gene therapy against metastasis. Previously we reported that a modification of PEG strongly suppresses the transition of PEG-Ad into the liver, thereby prolonging the circulating lifetime of Adv and leading to the accumulation of Adv in the tumor due to the EPR effect. 17) In particular, systemic administration of PEGAd with about 90% modification rate showed higher accumulation (17 times) and gene expression (35 times) in primary tumor tissue due to the EPR effects, and lower accumulation (17%) and gene expression (6%) in liver, compared to unmodified Adv. The EPR effect is observed in most solid tumors, whether primary or metastatic in nature. 27 ) Therefore, we propose that, in this study, PEG-Ad (90%) accumulated specifically in metastatic colonies due to the EPR effect, where it induced strong antitumor effects, although we did not examine the actual distribution of PEG-Ad and gene expression efficiency of TNFa of PEG-Ad in this study.
PEGs with different molecular weights have different body distribution patterns and retention times of materials which have been PEGylated in blood after intravenous injection. 28, 29) Modification of Adv with 20-kDa PEG decreases liver transduction in vivo compared with modification with 5-kDa PEG. 13, 21) Recently, we demonstrated that Adv modified with 20-kDa PEG markedly broadens the therapeutic range of Adv. 18) We are currently examining the capacity of Adv modified with 20-kDa PEG to evade pre-existing anti-Adv Abs and reduce humoral immune responses. Furthermore, although we used PEG-Ad with universal CMV promoter typically used in Adv constructs, it would be more effective for systemic cancer gene therapy to use PEG-Ad with tumor specific promoter such as the human telomere reverse transcriptase (TERT) promoter, which restrict transgene expression to tumor tissue alone. These transductional and transcriptional tumor targeting approaches would enable more effective and safer systemic cancer gene therapy using Adv.
In the present study, we demonstrated that systemic injection of PEG-Ad, with an appropriate PEG modification rate of 90%, reduces the production of anti-Adv Abs. In addition, we showed that systemic injection of PEG-Ad encoding TNFa gene at this modification rate produces substantial therapeutic effects against metastatic cancer. The detail relation between the production of anti-Adv Abs via multiple administration and the therapeutic efficacy is still unclear, and it would be the subject of future investigation. These results provide important basic information for the therapeutic application of Adv for cancer gene therapy. 
